ReviewArquivos de neuro-psiquiatria2022
Update on the diagnosis and management of neurocysticercosis.
Review in Arquivos de neuro-psiquiatria, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Impact of albendazole treatment on the symptom profile of neurocysticercosis patients 14-16 years following diagnosis.Parasitology · 2025Trial
- Neuroimaging Features of an Experimental Model of Extraparenchymal Neurocysticercosis.Acta parasitologica · 2026Article
- Atypical Hemorrhagic Presentation of Neurocysticercosis in a Patient on Chronic Anticoagulation.Cureus · 2026Article
- Taenia solium neurocysticercosis: Its current epidemiological, diagnostic, therapeutic, and control landscapes.PLoS neglected tropical diseases · 2026Review
- Repair capacity ofFuture microbiology · 2025Article
- The hidden threat of cysticercosis: A neglected public health problem.Open veterinary journal · 2025Review
- Racemose Neurocysticercosis Presenting As Vasculitic Infarct and Obstructive Hydrocephalus: A Rare Presentation.Cureus · 2025Article
- The Pathological Fear of COVID-19 and Neuroparasitosis: A Case Report of Neurocysticercosis.Cureus · 2025Article
- Racemose neurocysticercosis mimicking craniopharyngioma.Revista da Sociedade Brasileira de Medicina Tropical · 2025Article
- Current Role of Surgery in the Treatment of Neurocysticercosis.Pathogens (Basel, Switzerland) · 2024Review
- From laboratory to clinical practice: an update of the immunological and molecular tools for neurocysticercosis diagnosis.Frontiers in parasitology · 2024Review
- Metagenomic next-generation sequencing in the diagnosis of neurocysticercosis: A case report.World journal of clinical cases · 2023Article
- Consistent Measurement of Parasite-Specific Antigen Levels in Sera of Patients with Neurocysticercosis Using Two Different Monoclonal Antibody (mAb)-Based Enzyme-Linked Immunosorbent Assays.Pathogens (Basel, Switzerland) · 2023Article
- Article
- Human Neurocysticercosis: An Overview.Pathogens (Basel, Switzerland) · 2022Review
- New animal models of neurocysticercosis can help understand epileptogenesis in neuroinfection.Frontiers in molecular neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurocysticercosis (NCC) is a serious public health problem in several developing countries, including those in Latin America, Asia, and Africa. NCC is considered to be the main cause of late-onset epilepsy in endemic areas.
objectiveThis review summarizes recent advances in diagnosis and therapy of NCC. Methods: Relevant articles and books were reviewed and used as a source of information for this review.
resultsThe diagnosis of NCC is based upon neuroimaging studies (MRI and computed tomography) and laboratory analysis of the cerebrospinal fluid (CSF). Praziquantel and albendazole are considered parasiticidal drugs against NCC, but there is an intense debate over the value and safety of these drugs.
conclusionGiven the relative scarcity of clinical trials, more comparative interventional studies, especially randomized controlled trials in long-term clinical evolution, are required in order to clarify the controversy over the validity of parasitic therapy in patients with NCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.